{"url":"https://newsforagent.com/news/2026-11-06/molecular-partners-mp0632-preclinical-sitc","markdown_url":"https://newsforagent.com/news/2026-11-06/molecular-partners-mp0632-preclinical-sitc.md","title":"Molecular Partners MP0632 Data Back IND-Enabling Studies","headline":"Molecular Partners Reports MP0632 Preclinical Safety Data at SITC 2026","description":"Molecular Partners presented preclinical MP0632 data at SITC 2026 showing no detectable impact on healthy mesothelial or epithelial cells.","section":"Research & Clinical Trials","published_at":"2026-11-06T06:22:18+00:00","modified_at":"2026-11-06T06:22:18+00:00","author":"News Desk","key_takeaways":["Molecular Partners presented preclinical MP0632 data at SITC 2026 showing no detectable impact on primary human mesothelial or epithelial cells.","MP0632 is a logic-gated Switch-DARPin T cell engager designed to activate only when MSLN and EpCAM are both present.","The data support advancing MP0632 into IND-enabling studies for solid tumors co-expressing MSLN and EpCAM, including ovarian, endometrial, lung and pancreatic cancers."],"companies":[{"name":"Molecular Partners","is_primary":true,"profile_url":"https://akta.pro/company-profiles/0002bso/molecular-partners","website":"https://www.molecularpartners.com"}],"source":{"publisher":"Stock Titan","title":"Molecular Partners MP0632 data show preclinical safety","url":"https://www.stocktitan.net/news/MOLN/molecular-partners-presents-new-preclinical-data-for-next-generation-celh6ed50wpc.html"},"other_sources":[],"tags":["Research & Clinical Trials","Molecular Partners"],"body_markdown":"Molecular Partners presented preclinical data for its T cell engager MP0632 at SITC 2026, showing no detectable impact on primary human mesothelial or epithelial cells, the company said in a [Stock Titan](https://www.stocktitan.net/news/MOLN/molecular-partners-presents-new-preclinical-data-for-next-generation-celh6ed50wpc.html) report on November 6, 2026. The results support advancing MP0632 into IND-enabling studies for solid tumors co-expressing MSLN and EpCAM.\n\n## What The MP0632 Poster Showed\n\n[Molecular Partners](https://akta.pro/company-profiles/0002bso/molecular-partners) is a clinical-stage Swiss biotech developing DARPin therapeutics, with a focus on targeted radiotherapeutics. MP0632 is a logic-gated Switch-DARPin T cell engager with integrated CD2 co-stimulation, designed to activate T cells only when both MSLN and EpCAM are present.\n\nThe SITC poster, #1072 and a Top 150 SITC 2026 Abstract, reported potent and selective tumor cell killing with efficacy comparable to a clinical-stage benchmark T-cell engager but a substantially improved safety profile. The data showed safe integration of CD2 co-stimulation enabling sustained T-cell activity, and no evidence of mononuclear cell infiltration in the lung pleura of mice expressing human EpCAM and MSLN.\n\n\"These new data highlight that our logic-gated Switch-DARPin TCEs can address one of the central challenges in solid tumors: achieving potent anti-tumor activity while avoiding side-effects on healthy tissues that express the same targets,\" said Martin Steegmaier, Ph.D., Chief Scientific Officer of Molecular Partners. The company said the findings build on previously presented data showing regression of established tumors expressing both EpCAM and MSLN, with minimal impact on tissue expressing only one antigen.\n\n## Molecular Partners' Pipeline And Partnerships\n\nAccording to akta.pro [company records](https://akta.pro/company-data), Molecular Partners' pipeline includes 10 programs, among them MP0712 targeting DLL3, MP0726 targeting MSLN, MP0533 in AML, MP0317 in solid tumors, MP0632 and MP0621. The same records list a co-development agreement with Orano Med signed in January 2024 for Radio-DARPin therapies using 212Pb targeted alpha therapy, initially covering four programs and expanded in January 2025 to include six additional programs.\n\n## Earlier Molecular Partners Updates\n\nMolecular Partners said on November 5, 2026 that it will present its DLL3-targeting Radio-DARPin MP0712 at the 2026 SNMMI Theranostics Conference and NACLC 2026, according to GlobeNewswire. On October 29, 2026, Stock Titan reported that the company held CHF57.5M in cash as of September 30, 2026, expected to fund operations into late 2027, and would reduce up to 55 positions by Q2 2027. FinancialContent Business Page reported on October 22, 2026 that Molecular Partners selected MP0730 as its lead Radio-DARPin candidate targeting CD70, with a first-in-human program expected to start mid-2027.\n\n## MP0632 Poster Timing At SITC\n\nThe MP0632 poster is scheduled for viewing on November 7, 2026, from 12:30-1:30 and 6:40-8:10 pm MT at the Phoenix Convention Center. Molecular Partners said the poster will be made available on its [website](https://www.molecularpartners.com) after the presentation.\n","publisher":{"name":"News for Agent","url":"https://newsforagent.com"}}